MyMD Pharmaceuticals, Inc. (MYMD): history, ownership, mission, how it works & makes money

Born in 2014 to tackle age-related and inflammatory diseases, MyMD Pharmaceuticals - rebranded in July 2024 as TNF Pharmaceuticals (TNFA) - has pivoted squarely toward TNF-alpha biology with an oral lead candidate, MYMD-1, and a synthetic cannabidiol program, Supera-CBD, while operating R&D facilities in Baltimore; the company completed a 1-for-30 reverse split in February 2024 and regained Nasdaq compliance in March 2024 before beginning to trade under the new ticker on July 24, 2024, secured a strategic $7.0 million investment from PharmaCyte Biotech in May 2024, published Phase 1 MYMD-1 safety/tolerability data in Drug Research in July 2025, and today sits as a micro-cap with a market capitalization of approximately $2.12 million (as of June 18, 2025) while reporting $0.00 million in net sales and a net loss of $14.68 million over the latest four quarters, backed by $14.72 million in shareholders' equity and $21.42 million in total assets as of December 24, 2024, and pursuing revenue through strategic investments, partnerships, licensing, and potential commercialization pathways

MyMD Pharmaceuticals, Inc. (MYMD) - Intro

• Founded in 2014 to develop novel therapies for age-related diseases, autoimmune and inflammatory conditions.
• February 2024: executed a 1-for-30 reverse stock split to address low share price.
• March 2024: regained compliance with Nasdaq minimum bid price requirement following the reverse split.
• May 2024: secured $7.0 million in strategic investments from PharmaCyte Biotech, Inc. to advance clinical programs.
• July 2024: rebranded to TNF Pharmaceuticals, Inc. to align corporate identity with scientific focus on TNF-alpha.
• July 24, 2024: began trading on the Nasdaq Capital Market under ticker symbol TNFA (replacing MYMD).
• July 2025: published Phase 1 data for oral TNF-alpha inhibitor MYMD-1 in Drug Research showing favorable safety and tolerability.

• Mission: develop oral and biologic therapies that modulate TNF-alpha and related inflammatory pathways to treat autoimmune, inflammatory, and age-related diseases.
• Primary therapeutic strategy: oral TNF-alpha inhibition (lead program MYMD-1) intended to provide systemic anti-inflammatory effects without injectable biologic drawbacks.
• Research emphasis: translate preclinical TNF-alpha modulation into clinically meaningful safety and tolerability profiles to enable chronic use.

• Publicly traded company (previous ticker MYMD; current ticker TNFA as of 7/24/2024 on Nasdaq Capital Market).
• Key capital event: $7.0M strategic equity infusion from PharmaCyte Biotech in May 2024 to support clinical development and operations.
• Corporate action: 1-for-30 reverse split (Feb 2024) used to meet Nasdaq listing standards; compliance restored in March 2024.

• Discovery and preclinical: identify small-molecule oral inhibitors targeting TNF-alpha pathways and optimize pharmacokinetics for oral dosing.
• Clinical development: Phase 1 → Phase 2 → registration-directed trials, with published Phase 1 safety/tolerability data for MYMD-1 (Drug Research, July 2025).
• Partnerships and strategic financing: use equity investments and collaborations (e.g., PharmaCyte) to de-risk and fund clinical milestones.
• Regulatory strategy: pursue standard FDA clinical pathway for novel systemic anti-inflammatory agents with safety-focused endpoints in early trials.

• Equity financing and strategic investments to fund operations and trials (example: $7M from PharmaCyte, May 2024).
• Collaborations, licensing and milestone payments-partnering out programs or licensing regional rights upon clinical success.
• Potential future revenue streams: product sales from approved drugs (e.g., MYMD-1), royalties from out-licensed assets, and milestone/licensing receipts.
• Capital markets activity: public equity (ticker transition to TNFA) enables access to public investors for follow-on financings.

MyMD Pharmaceuticals, Inc. (MYMD): History

• Two wholly owned subsidiaries: Akers Acquisition Sub, Inc. and Bout Time Marketing Corporation.
• Common stock listed on the Nasdaq Capital Market under ticker symbol 'TNFA'.
• May 2024: PharmaCyte Biotech, Inc. made a $7.0M strategic investment, signaling external interest.

• Ownership structure: micro-cap public company with concentrated institutional and strategic holders following the $7M investment; public float and exact major holders vary over time.
• Liquidity profile: market cap near $2.12M implies low trading liquidity and heightened volatility risk for equity holders.

MyMD Pharmaceuticals, Inc. (MYMD): Ownership Structure

• Lead candidate: MYMD-1 - an oral TNF-alpha inhibitor designed for autoimmune and inflammatory indications.
• Scientific validation: Phase 1 data published in Drug Research showing favorable safety and tolerability.
• Strategic capital: $7,000,000 investment from PharmaCyte Biotech in May 2024 to advance clinical programs and collaborations.
• Core values: scientific rigor, translational focus on chronic inflammation, and partnerships to accelerate development.

• How the company makes money: pursue clinical advancement of MYMD-1 to create licensing opportunities and partner-driven development; monetize through upfronts, milestones and royalties while using equity and partner investments to fund trials.
• Strategic priorities for investors/partners: advance pivotal-stage data, broaden indication footprint (autoimmune, inflammatory, age-related conditions), and secure partnerships that provide non-dilutive capital and commercial expertise.

MyMD Pharmaceuticals, Inc. (MYMD): Mission and Values

• Headquarters / research: Baltimore, Maryland facilities with advanced analytical platforms for preclinical and clinical development.
• Core technologies: oral TNF-alpha modulation (MYMD-1) and synthetic cannabidiol chemistry (Supera-CBD).
• Clinical focus: sarcopenia, chronic inflammatory conditions, CNS disorders and pain/addiction indications.

• MYMD-1 mechanism: a small‑molecule, oral TNF‑alpha inhibitor designed to regulate immune activity by modulating TNF‑alpha signaling, a central driver of chronic inflammation.
• Oral delivery advantage: MYMD-1 is formulated for oral dosing, avoiding injections or infusions typical of biologic TNF inhibitors and enabling easier outpatient and chronic administration.
• Blood-brain barrier penetration: MYMD-1 has been engineered to cross the blood-brain barrier, enabling potential treatment of CNS‑related inflammatory and neurodegenerative disorders.
• Supera‑CBD: a synthetic cannabidiol derivative intended to provide controlled, scalable cannabinoid therapy aimed at chronic pain, addiction and epilepsy with defined chemistry and IP protection.

• MYMD-1 has progressed through preclinical studies and into clinical testing, including completion of a Phase 2 trial for sarcopenia.
• Company‑reported outcomes: clinical pharmacology and Phase 2 data show target engagement and signal(s) consistent with modulation of inflammation and potential improvement in muscle health associated with sarcopenia.
• Development rationale: by reducing pathologic TNF‑alpha activity systemically and within the CNS, MYMD-1 aims to slow processes linked to aging and extend healthy lifespan metrics under study.

• Value creation through R&D: advancing small‑molecule assets (MYMD‑1, Supera‑CBD) to generate clinical value and IP.
• Partnering and licensing: potential milestone, royalty and licensing revenues from partnerships with larger pharma for late‑stage development and commercialization.
• Out‑licensing of specific indications/formulations and technology transfer of synthetic cannabinoid platforms.
• Capital markets and grants: financing via equity placements, public market transactions and potential government or foundation research grants to fund development programs.

• Platform advantage: oral TNF modulation intended to replicate benefits of biologic TNF inhibitors without parenteral administration; designed to access both peripheral and central compartments.
• Manufacturing and chemistry: synthetic cannabinoid program built for scalable, GMP‑compatible production of Supera‑CBD derivatives.
• Research site: Baltimore labs support medicinal chemistry, PK/PD, bioanalytical and formulation activities.

MyMD Pharmaceuticals, Inc. (MYMD): How It Works

• Research & development: discovery, preclinical validation, IND-enabling studies, and phased clinical trials (Phase 1-3).
• Partnerships & licensing: collaborative R&D, out‑licensing of assets, co-development and commercialization agreements.
• Capital formation: equity raises, debt financing, and strategic investments to fund trial milestones and scale operations.
• Technology transfer & asset sales: selling proprietary compounds, platforms, or technology rights to third parties.

• Strategic investments: direct infusions from industry partners and investors to support clinical programs (example: strategic investments such as the $7.0 million from PharmaCyte Biotech in May 2024).
• Partnerships and collaborations: milestone payments, shared-development funding, and cost-sharing with biotech firms and academic institutions.
• Licensing agreements: upfront fees, development and regulatory milestones, and tiered royalties (typically structured as low-double-digit royalty rates on net sales for similar small-cap biotech deals).
• Grants & subsidies: government and non-dilutive R&D grants for specific indications or platform development.
• Asset sales & technology transfers: one-time receipts from selling proprietary compounds, formulations, or delivery platforms.
• Public offerings & debt: equity raises (private placements, public follow‑on offerings) and convertible or term debt to finance operations.

• Out‑licensing late-stage candidates to larger pharma to unlock near-term non-dilutive value and future royalty streams.
• Co-development agreements that share cost and risk while preserving upside through equity/royalty participation.
• Strategic collaborations with academic centers for biomarker-driven indications, often tied to grant funding.

MyMD Pharmaceuticals, Inc. (MYMD): How It Makes Money

• Pipeline commercialization - advancing MYMD-1 through mid-stage clinical trials with Phase 2 positive data in sarcopenia signals future productization and out-licensing or direct commercialization opportunities.
• Indication expansion - clinical development into rheumatoid arthritis and Hashimoto's thyroiditis aims to broaden addressable markets and increase lifetime revenue per asset.
• Cannabidiol therapeutics - Supera-CBD development targets the growing CBD-based treatment market for chronic pain and neurological disorders.
• Strategic partnerships & investments - collaborations to co-develop, fund, or commercialize assets reduce capital burden and create milestone and royalty revenue paths.

• Corporate rebranding/market identity: As of July 24, 2024, TNF Pharmaceuticals' stock began trading under the ticker symbol 'TNFA,' reflecting rebranding and strategic focus (reported in market disclosures).
• Exchange compliance: The company has regained compliance with Nasdaq's minimum bid price requirement (the typical minimum is $1.00 per share), indicating improved market stability and access to public capital markets.
• Clinical progress: MYMD-1's positive Phase 2 results in sarcopenia underpin near-term value inflection points (upcoming mid-stage trial milestones, potential end-of-Phase-2 meetings with regulators, and partnership interest).
• Indication growth strategy: Active exploration of rheumatoid arthritis and Hashimoto's thyroiditis increases addressable patient populations and potential peak sales scenarios.
• Cannabinoid opportunity: Development of Supera-CBD targets an expanding global market for CBD therapeutics; market forecasts commonly project multibillion-dollar segments for pain and neurological indications over the next 5-10 years.
• Capital & partnership signals: Recent strategic partnerships and investment activity suggest expanded runway and de-risked development pathways, enabling scale-up toward commercialization.

• Upfront payments and milestones from licensing or co-development deals
• Royalties on partnered product sales
• Direct product sales if the company commercializes therapeutics itself
• Research collaborations, grants, and non-dilutive funding supporting R&D
• Asset sales or spin-outs for non-core programs